Introduction
Colorectal cancer (CRC) remains an important public health problem [1] and a leading cause of cancer-related mortality worldwide [2] . Earlier diagnosis and improved treatments [3] mean that more patients are likely to survive longer after a CRC diagnosis [4] . These survivors are also at increased risk of mortality from other cancers and noncancer causes [5] .
Despite the significantly increased risks of subsequent malignancies in CRC patients being extensively documented [6, 7] , the survival impact of secondary cancers has not been well established. Using a clinical trial database in the United States, Zamboni and colleagues reported poorer conditional survival for nearly 7,000 CRC patients subsequently diagnosed with second cancers [8] , whereas a hospital-based review of about 1,000 Korean patients [9] found no significant differences in mortality risk. However, the smaller sample size and inherent selection bias of such studies can limit their applicability to the general population.
The standard Kaplan-Meier estimator of CRC survival, which censors non-CRC mortality rather than specifically acknowledging that patients dying from other causes are no longer at risk of CRC mortality, may be biased in competing risk situations [10] . The recommended approach [10, 11] for estimating the probability of mortality occurring in a competing risk setting is to use cumulative probability functions (CPFs). The CPF is a function of the hazards for all competing events, so only persons who remain alive are considered at risk of CRC mortality. In contrast, the Kaplan-Meier estimator which only considers the hazard for CRC mortality treats people who die from competing events as censored [10, 12] .
Similarly, covariate effects in cause-specific Cox proportional hazards models pertain solely to CRC mortality without considering how the covariates act on competing events. Their interpretation in terms of survival probabilities can therefore be misleading in competing risk situations [10, 11] . An alternative approach that directly models covariate effects on the cumulative probabilities for different types of mortality was proposed by Fine and Gray [13] . These Fine and Gray models are being increasingly used to explore predictors of site-specific and competing mortality for various cancers and thus develop prognostic models for stratifying patients according to their competing mortality risks [14] [15] [16] .
The choice between the widely accepted Cox proportional hazards model and the Fine and Gray competing risk methodology depends on the research question(s) of interest. Since the first approach focuses on the covariates associated with risk of CRC mortality, it is well suited to assess whether potential prognostic factors are indeed associated with an increased hazard of CRC mortality. However, simply modeling the covariate effects on CRC mortality gives an incomplete picture of the mortality faced by people diagnosed with CRC, because it ignores deaths caused by other conditions. If the interest is in identifying predictors of competing mortality, then modeling covariate effects on the cumulative probabilities of all mortality events is essential. These differences are important since a covariate may appear to increase the probability of CRC mortality simply by lowering the rate of occurrence of non-CRC mortality even if it does not affect the rate of CRC mortality [10, 11, 15, 17] .
In this study, we used competing risk methodology to examine the impact of various demographic and clinical factors on the probability of mortality from CRC, other cancers, or non-cancer causes for a large population-based cohort of CRC patients from Queensland, Australia. To our knowledge there have been no large-scale populationbased epidemiological studies with long-term follow-up examining the predictors of mortality risks among CRC survivors from cancer and then separately from non-cancer causes. This information is crucial to inform the development of a criterion framework for individually tailored therapies by identifying patient subgroups at higher risk for competing events or CRC-specific mortality.
Methods
Ethical approval to conduct this study was obtained from the University of Queensland Social and Behavioural Sciences Ethical Review Committee. Queensland Health gave legislative consent to access routinely collected populationbased cancer incidence data in Queensland and to link this with the Queensland Hospital Admitted Patient Data Collection [18] .
Study cohort
All incident cases of invasive CRC (ICD-O-3 codes C18-C20, C21.8) diagnosed between 1 January 1996 and 31 December 2007 (inclusive) were extracted from the state-wide population-based Queensland Cancer Registry, to which all confirmed invasive cancers diagnosed among Queensland residents must be legally reported [19] . We then restricted our cohort to those aged 20-79 at diagnosis since CRC is very rare among younger individuals and inaccuracies in death certification are more likely in the older age group [20] . Variables extracted included age, year, sex, marital status, occupation, CRC site (colon C18; rectum C19-C20, C218), country of birth, and incidence of subsequent primary cancers (to 31 December 2009). Our choice of covariates was restricted to those collected by the registry or accessible from administrative databases. Second primary cancers were defined according to IARC rules [21] as histologically distinct invasive tumors that developed after a prior cancer diagnosis. Individuals were classified as having either a synchronous (diagnosed within 2 months) or metachronous (diagnosed after 2 months) second cancer, while those diagnosed with both these types (0.2 % of the final cohort) were included in the ''metachronous'' group [6] . Patients with no further primary cancers were categorized as ''solitary'' CRC cases.
Treatment and comorbidities
A deterministic linkage between the Queensland Cancer Registry and the Queensland Hospital Admitted Patient Data Collection provided information on CRC-related surgery and hospital comorbidities. The latter are defined as a condition that either co-exists with the principal diagnosis (CRC) or arose during a hospital stay and which influence a patient's clinical management [18] . The ICD-10-AM diagnostic codes [22] from hospital records were used to identify the most frequently occurring comorbidities for our cohort, namely diabetes (E10-E14), cerebrovascular (I60-I64), heart (I20-I50) and kidney disease (N00-N05, N10-N19).
Colorectal cancer staging
The procedure used to extract CRC stage at diagnosis using information recorded on pathology forms has been described previously [23, 24] . Localized cases (stages I-II) were collectively classified as ''early stage,'' while regional and metastatic disease (stages III-IV) were categorized as ''advanced stage'' [7] to allow sufficient numbers for modeling.
Travel distances
Actual road travel distances from a patient's residence to the closest radiation facility were calculated using geographical information system software and a street network database on a year-specific basis to account for the increasing coverage of such facilities over time [24] . Where full address details were not available (13.1 % of records in the final cohort), location was geocoded to the centroid of the patient's postcode at diagnosis. Radiation centers in Queensland are generally affiliated to major centers for cancer care; hence, these distances are a proxy measure of access to optimum cancer treatment.
Survival data
The cohort was followed up to 31 December 2009, a minimum of 2 years from the time of initial diagnosis for each patient who was still alive at the end date. Survival was measured in days from date of CRC diagnosis to date of death or study end point. Causes of death were classified as CRC, other cancer causes, or non-cancer causes. The Queensland Cancer Registry obtains details for all cancer patients who died in Queensland from the Registrar of Births, Deaths and Marriages [19] . Data matching with the National Death Index [25] and the Australian Bureau of Statistics [19] allows identification of interstate deaths. Case-specific reviews by specialized cancer coders using additional clinical information from various sources including pathology records, hospital data, and autopsy reports to that in the death certificate are used to finalize cause of death. This allows a high degree of accuracy. However, as with all registry-based studies, the potential misclassification of cause of death remains a possibility.
Statistical analysis
The ''stcompet'' command in Stata [26] was used to calculate the crude cumulative probability of cause of death while accounting for the dependence of the CPF on the hazards of all competing events. The resulting curves were compared across patient subgroups by the Pepe and Mori test [27] , which is based on cumulative weighted differences of the cause-specific probabilities between two groups. The impact of censoring and death among the cohort is to progressively reduce the effective sample size over time. To reflect this, the weight used in the Pepe and Mori test decreases with increasing time after diagnosis so that differences at earlier time points when the sample size is large are given more importance than differences at later time points [17] . Since we were comparing two categories with the baseline category, we used a more conservative significance cutoff of p \ 0.025 for this analysis.
We then used the competing risk regression method of Fine and Gray [13] to estimate covariate effects on the probability of mortality due to CRC, other cancers, and non-cancer causes. This approach allows direct modeling of the CPF for competing risks data by using a quantity that corresponds to the hazard of the sub-distribution for the failure event of interest, known as the sub-distribution hazard [13] . The sub-distribution hazard can be thought of as the probability of failure due to cause k at a given time, conditional on no cause k failures having occurred so far [11] . This method distinguishes between patients who are still alive and those who have already died from competing causes through weighted estimators [13] . Only those people who are still alive at the end of the follow-up period are considered censored. This approach also allows direct interpretation of the covariate effects on the CPF since the interpretation of the sub-hazard ratios is similar to that of hazard ratios. This means that an exponentiated positive regression coefficient for a covariate category implies a higher predicted probability of mortality compared to the reference category [28] . These competing mortality risks are not independent since a higher risk of death from one cause implies a lower risk of another cause. Estimated CPF using competing risks approach was compared visually to those generated using the standard Kaplan-Meier method [29] .
Potential violations of the proportional hazards assumption were tested by treating each covariate as a time-varying coefficient and including these in the final model only if the time-varying components were statistically significant [30] . Parameter estimates from the Fine and Gray models are presented as sub-hazard ratios (SHRs which can be thought of as the hazard ratio for the probability of failure due to a specific cause at a given time Cancer Causes Control (2013) 24:897-909 899 (that is, the sub-distribution hazard) with 95 % confidence intervals (95 % CIs). Estimates were initially adjusted for age at first cancer diagnosis, sex, country of birth, marital status, occupation, stage, site, surgical treatment, diabetes, other comorbidities, travel distance, and secondary cancers. All available covariates ( Table 2) that were significant at p B 0.20 in the initial multivariate analysis were retained in the final models.
All analyses were performed with Stata version 12.1 (StataCorp, TX).
Results

Study cohort
Between 1996 and 2007, there were 27,756 invasive CRC cases in Queensland of which 22,488 who were aged 20-79 years at diagnosis initially comprised the study cohort. The exclusion of patients who survived less than 2 months (n = 1,101, 4.0 %) and those who had a prior diagnosis of another invasive cancer (n = 1,972, 7.1 %) left a final cohort of 19, 415 patients with a first primary CRC.
More than half (57.6 %) of this cohort were male, 63.8 % were initially diagnosed with colon cancer, and the median age at first diagnosis was 66 years. (interquartile range: 57-72 years) Around a third (36.3 %) had advanced disease, 7.6 % had diabetes, 3.4 % had another of the specified comorbidities, and the majority (87.4 %) underwent CRC-related surgery. There were 535 (2.8 %) synchronous and 2,026 (10.4 %) metachronous secondary primaries recorded over the study period.
Mortality from colorectal cancer and competing causes
During the follow-up period (median 4.5 years, interquartile range 2.2-13.7 years), 8,106 patients (41.8 %) died, with 5,937 (73.2 %) of these deaths resulting from CRC, 560 (6.9 %) from other cancers, and 1,609 (19.9 %) from non-cancer causes. Table 1 summarizes available characteristics by mortality status.
The overall 5-year cumulative probabilities of mortality due to CRC, other cancers, and non-cancer causes were 29.4 % (95 % CI 29.3, 30.7), 2.0 % (95 % CI 1.8, 2.2), and 5.7 % (95 % CI 5.3, 6.0), respectively (Fig. 1) .
A comparison of the overall 5-year cumulative probability of mortality (with 95 % CI) estimated by KaplanMeier and competing risks approaches suggests that the former consistently overestimates the probability of competing deaths due to other cancers or non-cancer causes.
(Online Resource 1) Estimated curves by CRC stage (Fig. 2 ) and diagnosis age (Fig. 3) are also shown. The mortality curves for these particular covariates have been illustrated because they were generally representative of the magnitude of the differences between the cumulative probability curves estimated by the two methods, particularly for other cancers and non-cancer mortality.
CRC mortality
The unadjusted probability of CRC mortality was lower for females, those born in non-English-speaking countries, surgically treated cases, and those with metachronous secondary cancers ( Table 2 ). Higher probability of CRC mortality was evident for patients who were unmarried, in blue-collar occupations, diagnosed with advanced disease, had comorbidities other than diabetes, or lived further away from major cancer treatment centers.
Other cancer causes of mortality
Significant predictors of lower mortality risk from other cancers were younger age, being female, birth in nonEnglish-speaking countries, and advanced stage ( Table 2) . In contrast, a surgical treatment and (as expected) a second cancer diagnosis (either synchronous or metachronous) were associated with greater likelihood of mortality from other cancers.
Non-cancer causes of mortality
Patients who were younger, female, had advanced CRC, or developed metachronous second primaries were less likely to die from non-cancer causes, whereas increased noncancer mortality was associated with being unmarried, in blue-collar occupation, and having diabetes, or other comorbidities (Table 2) .
Competing risk analysis
CRC mortality
Following multivariate competing risks regression, significant independent predictors for increased CRC mortality were being female, unmarried, in blue-collar occupations, advanced stage, comorbidities except diabetes, and increasing travel distance (Table 3) . Younger age at diagnosis, birth in non-English-speaking countries, surgery, and second primary cancers (particularly metachronous) were independently associated with decreased mortality from CRC. Other cancer mortality
The probability of competing mortality due to other cancers was lower for CRC patients aged below 60 years than those aged 60-79 years. In addition to the diagnosis of metachronous second cancers, other predictors of increased other cancer mortality were being unmarried or in bluecollar occupations.
Non-cancer mortality
Increased non-cancer mortality was associated with being younger, unmarried, an initial colon cancer diagnosis, diabetes, and other comorbidities, whereas being female, advanced stage, surgery, and metachronous second cancers were statistically significant predictors of lower non-cancer mortality. While females had significantly lower probability of CRC mortality in the bivariate competing risk analysis (Table 2) , the direction of this association was reversed in the final multivariate model (Table 3 ). Further analysis (not shown) found evidence of a significant interaction effect (p \ 0.001) between sex and occupation, with females in the unemployed/not known category having increased risks of CRC mortality compared to males. In contrast, there was no significant (p [ 0.05) evidence for a gender difference among the other occupation categories for CRC mortality, nor for the other types of mortality.
Discussion
Using a large population-based cohort of CRC patients, we identified various prognostic factors for CRC mortality and competing mortality from other cancers or non-cancer causes. Little is currently known about risk factors for competing mortality in CRC patients, particularly those based on competing risks methodology. We found that the standard Kaplan-Meier approach tends to overestimate mortality risks due to non-cancer or other cancers causes. To our knowledge, this is the first Australian study to explore predictors of competing mortality for CRC survivors in Australia. Internationally, one population-based study from the United States reported increasing age, male sex, localized disease, and comorbidities to be significant predictors of non-CRC mortality [31] . However, that study combined all non-CRC deaths into a single category and the analysis was restricted to patients aged over 65 years. Although the significantly increased probability of other cancer mortality for CRC patients having second primary cancers in our cohort was intuitively obvious, we provide quantitative evidence for synchronous versus metachronous cancers. Moreover, being diagnosed with a second cancer was protective in terms of CRC mortality and also non-cancer mortality in the case of metachronous cancers.
Gender differences in unmeasured biological, environmental, and lifestyle factors [32, 33] probably contributed to the observed variations in mortality probabilities between males and females in our cohort. For example, less aggressive treatments [32] and higher treatment-related toxicities have been reported for women [33] although men have higher risks of chronic diseases and adverse health behaviors [34] .
The survival advantage for married patients in our cohort may reflect increased social support to buffer the negative impact of stress-related biological processes and greater practical assistance while undergoing treatment [35] . Occupation can be seen as a measure of individual socioeconomic disadvantage; again, underlying variations in currently unmeasured factors associated with socioeconomic status [36, 37] may have impacted the results.
The protective effect of surgery on non-cancer mortality suggests that surgery may be a proxy for factors such as better overall health and higher level functional status. Increased medical surveillance following surgery may also result in the earlier detection and more timely treatment of comorbidities [38] .
Age and comorbidities (except diabetes) were associated with increased probabilities of both CRC and competing mortality for patients in our cohort. Advancing age has been related to inadequate surgery, non-receipt of multimodal therapies, reduced therapeutic efficacy, and multiple comorbidities [33, 39] . Comorbidities themselves can significantly influence the clinical management of CRC patients [40] , while diabetes in particular is associated with an increased likelihood of other chronic conditions as well as risk factors (notably obesity) for poorer prognosis. Residual confounding by unmeasured lifestyle and patient factors is also likely [40, 41] . We lacked the necessary data to explore these issues further. The time lag for chronic comorbid conditions to manifest any adverse effects means that their prognostic impact is reduced if an advanced tumor or second cancer intervenes to cause an early death. Hence, for CRC patients with advanced disease or metachronous second primaries, it is cancer rather than other conditions that primarily determines the outcome.
The risks of competing mortality events have not traditionally being considered when developing evidencebased clinical guidelines. Our study reinforces the identified need for greater surveillance of CRC survivors [38] via routine screening and follow-up, along with multicomponent lifestyle interventions for preventing second cancers and reducing the risk of chronic diseases [5, 42] , particularly among older patients [5] . Improved understanding of the relationship between prognostic factors and competing mortality risks may also serve to identify opportunities for promoting primary preventive health behaviors especially among high-risk patient populations [43, 44] . This is especially important with the number of CRC survivors expected to increase over coming decades [5] .
At a minimum, a healthy and physically active lifestyle [44] that can reduce both the risk of developing second cancers and chronic diseases as well as aid in the clinical management of already existing diseases should be a priority for CRC survivors. Improved prevention and/or management of comorbidities can be beneficial not only in reducing competing mortality risks but also allow the completion of more aggressive treatment regimes that enhance the overall prognosis for CRC patients [45] .
This study adds to the growing body of international evidence that competing mortality events are important among cancer survivors and become increasing likely with advanced age, other cancers, and comorbidities [16, 46] . While we were limited in our capacity to control for all possible confounders and there is potential for misattribution of cause of death to have biased observed estimates to some extent [47] , we believe that the current results provide novel and important insights into the prognostic impact of various risk factors. They may also provide the foundation for more detailed studies incorporating various lifestyle factors and detailed treatment modalities to further elucidate the underlying mechanisms behind observed variations in competing mortality risks among CRC survivors. Such studies are currently lacking and would be informative in the development of more effective clinical strategies to optimize favorable outcomes and reduce mortality.
Study strengths include a large population-based cohort for whom data were collected independently of the study hypotheses. The high degree of histological verification within the Queensland Cancer Registry [19] allowed differentiation of new primaries from metastatic CRC. Linkage to an administrative database of hospital records within Queensland provided information on surgical status and selected comorbidities. However, this data would be missing for a small proportion of patients who received subsequent treatment interstate. Missing medical information may also be related to errors in notification or data matching processes [7] .
As the Queensland Cancer Registry does not collect data on receipt and completion of non-surgical procedures notably radiation and systemic therapies, treatment toxicities, and lifestyle factors, we were unable to control for these potential confounders [5, 33, 37, 42] . Information on individual comorbidities was limited to conditions recorded during a hospital stay and may not be comprehensive. Study results could also have been influenced by the lack of sensitivity and specificity of our occupation measure since it was not possible to disaggregate the ''unemployed/not known'' category into more homogenous groupings such as ''home duties,'' ''retired'' or unemployed' based on available data. The Queensland cancer registry also does not collect information on individual income and education.
Conclusions
This study has identified several important subgroups of CRC patients (such as being older, unmarried, with localized disease, comorbidities, or secondary cancers) who are at increased risk of dying from causes other than CRC. A better awareness among CRC patients and their doctors about the risk of competing causes of death, and the ability to quantify the extent of this risk, has the potential to translate into more effective individualized strategies for the clinical management of CRC cases. In particular, strategies that reduce the incidence or impact of comorbidities, including second cancers, through clinical management, education, and lifestyle changes should be a priority.
